Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > converting data

<< Previous

Bullboard Posts

Next >>

Comment by 2b7f6fabon Aug 30, 2021 9:29pm

268 Views

Post# 33786182

RE:RE:converting data

For the Optimized Study Chart the 90 day column appears to consider only 12 patients since there are 8.3% used in this column which would translate to 1/.083333 =12 patients.

There is no telling how many are used in the 180 day column, could be 12 or 15.

Jump over to 270 day column which has 6.7% is indicating 15 patients. 1/.0666667 = 15 patients. The 360 day and the 450 day isn't showing the 2 of 3 complete response from Ph1b.

Shrugs shoulders.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages